| CHARITE - UNIVERSITATSMEDIZIN BERLIN Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122243 | MEANS AND METHOD AND MEANS FOR DIAGNOSING PROSTATE CARCINOMAS - The present invention relates to a method, preferably an ex vivo method, for diagnosing prostate carcinomas and/or predisposition thereof comprising determining at least one metabolite in a test sample of a subject suspected to suffer from prostate carcinomas or to have a predisposition therefor and comparing said at least one metabolite to a reference, whereby prostate carcinomas or a predisposition therefor is to be diagnosed. Moreover, the present invention encompasses a collection of metabolites, a data collection comprising characteristic values of metabolites and a storage medium comprising said data collection. Furthermore, the present invention also relates to a system comprising means for comparing characteristic values of metabolites of a sample operatively linked to a data storage medium. Further encompassed by the present invention are diagnostic means comprising at least one metabolite and the use of said at least one metabolite for the manufacture of diagnostic means for or for diagnosing prostate carcinomas. Finally, the present invention pertains to a method for identifying prostate carcinoma-related metabolites. | 05-17-2012 |
| 20120070854 | HNRNP A3 Related Peptides and Use Thereof for Diagnosis of Rheumatoid Arthritis - The invention relates to a peptide and retro or retro-inverso peptide thereof, with a length of ≦25 amino acid residues, characterized in that the peptide comprises at least one citrulline residue, and exhibits a sequence identity over the whole sequence of the peptide of ≧70% compared to human hnRNP A3 protein (SEQ ID No. 1) and uses thereof. | 03-22-2012 |
| 20110311999 | DIAGNOSTIC PREDICTION OF RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS - The present invention pertains to a diagnostic assay for the diagnosis of an autoimmune disease. The present invention provides an improved diagnostic assay for the diagnosis of an autoimmune disease, particularly rheumatoid arthritis (RA) and Systemic Lupus Erythematosus (SLE). In particular the invention pertains to a method of determining in a sample of a subject the presence of two or more antibodies comprising the step of determining whether an antibody is present in a sample that specifically recognizes a hnRNP-DL polypeptide or a fragment thereof or a splice variant thereof and the further step of determining whether at least one further antibody is present in the sample that specifically recognizes a at least one other hnRNP polypeptide which is not sequence homologue to said hnRNP-DL polypeptide or fragments thereof or splice variants thereof, and/or said CCP peptide and/or a polypeptide comprising at least the Fc-part of IgG, respectively. The invention also relates to polypeptides, protein sets and antibodies that may be used in such methods and assays and for therapeutic use in RA and SLE patients. | 12-22-2011 |
| 20110190142 | DETERMINATION OF RENIN-PRORENIN RECEPTOR ACTIVITY - The present invention refers to the renin/prorenin receptor (RER) signal transduction pathway and, in particular, to the role of promyelocytic zinc finger protein (PLZF) and its downstream targets involved in this pathway, e.g. the p85α subunit of phosphatidylinositol-3 kinase (PI3K-p85α). In more detail, the present invention refers to a method for determination of RER activity, e.g. stimulation or inhibition of RER activity, using PLZF activity as a measurement from which RER activity is derived. For the determination of RER activity, use can be made of RER/PLZF protein interaction, PLZF translocation and/or PLZF recruitment. The present invention further refers to a use of said method for identifying RER ligands, e.g. pharmaceutically active agonists or antagonists, as well as for studying undesired side-effects of renin inhibitors. | 08-04-2011 |
| 20110077230 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION - The present invention relates to copper-organic complexes and pharmaceutical compositions containing the same. They can be used especially in the treatment of diseases caused by hyperproliferative cells and, in addition, protect healthy tissue from ionizing radiation. They are prepared by reacting a copper(II) acylate with an organic compound selected from 4-[bis(2-chloroethyl)amino]-D,L-phenyl-alanine (sarcolysine), the hydrochloride thereof, N-(2-furanidil)-5-fluorouracil (tegafur) and aminocarbonylaziridine (leacadin) at acidic to neutral pH in a chloroform/methanol mixture. | 03-31-2011 |
| 20110040766 | Methods for searching with semantic similarity scores in one or more ontologies - A method assigns importance ranks to documents within repositories or databases, such as any database of documents such as books or other printed material, electronic documentation, and pages within the world-wide web. The method uses a corpus of indexed documents that has been annotated to the terms of one or more ontologies in order to assign a semantic similarity score to queries based on terms taken from the ontologies. A statistical model is used to test the significance of matches between query terms and documents or categories. The method results in an acceleration of over 10,000-fold for realistic queries and ontologies, and makes it practicable to calculate P-values dynamically or to keep database annotations and the related P-value distributions up to date by frequent recalculation. | 02-17-2011 |
| 20110026356 | APPARATUS AND METHODF FOR THE UNIFORM DISTRIBUTION OF MICROPARTICLES IN A LIQUID - The invention relates to an apparatus for the uniform distribution of microparticles in a liquid, said apparatus comprising a storage chamber | 02-03-2011 |
| 20110015133 | PAX2 AND PAX8 AS TUMOUR TARGETS FOR IMMUNOLOGIC AND MOLECULAR TREATMENT STRATEGIES - Briefly, the present invention refers to the transcription factors PAX2 and PAX8 expressed in solid tumours and haematologic malignancies, and their utility as a target in immunotherapy and molecular therapy. In more detail, the invention refers to a method for identifying an immunogenic T-cell epitope from PAX2 and/or PAX8. Furthermore, the invention refers to a use of immunogenic T-cell epitopes, e.g. identified by said method, and their use as targets for the recognition by targeting means, e.g. T-cells or antibodies. The invention also refers to peptides representing immunogenic T-cell epitopes and their uses for the preparation of a pharmaceutical composition for immunotherapy of PAX2 and/or PAX8 expressing malignancies. | 01-20-2011 |
| 20110006767 | DEVICE AND PROCESS FOR MAGNETIC RESONANCE ELASTOGRAPHY (MRE) - The invention relates to a device to produce mechanical oscillations in a research object using magnetic resonance elastography (MRE) with a membrane that can be set into periodic motion ( | 01-13-2011 |
| 20100143880 | ANALYSIS METHOD FOR DETERMINING A FUNCTIONAL PARAMETER OF AN ORGAN USING PREFERABLY AN AQUEOUS 13C-METHACETIN SOLUTION - The invention relates to an analysis method for determining a functional parameter of an organ of a human or animal individual by measuring the | 06-10-2010 |
| 20100040587 | CELLS FOR THERAPY OF THE HEART, METHOD OF OBTAINING A CELL PREPARATION, AND CELL PREPARATION - Fibroblast-like cells obtained from heart muscle biopsies, which are CD90 negative, CD105 positive, CD117 negative and/or CD166 positive as well as cell preparations of such cells for therapy of heart diseases, as well as a method for providing the latter. The cells are characterized by a good cultivability in cell culture. Furthermore a method for obtaining the cells and cell preparations according to the invention are disclosed. | 02-18-2010 |
| 20090304622 | METHOD AND MEANS FOR INFILTRATING ENAMEL LESIONS - The present invention refers to a method of infiltrating enamel for the prevention and/or treatment of carious lesions comprising (a) exposing an enamel area to a conditioner comprising hydrochloric acid; (b) exposing the conditioned enamel area to an infiltrant; and (c) curing the infiltrant. The present invention further refers to a kit for carrying out the method of infiltrating enamel, which comprises a conditioner comprising hydrochloric acid and an infiltrant comprising at least one low viscous dental resin. Alternatively, the kit comprises ready-to-use means for carrying out the method of infiltrating enamel, e.g. application strips with delivery pads soaked with conditioner or infiltrant. The present invention also refers to a method for identifying an infiltrant by calculation of the penetration coefficient, and to an infiltrant identified by the method having a penetration coefficient of >50 cm/s or comprising a low viscous light curing resin having a penetration coefficient of >50 cm/s. | 12-10-2009 |
| 20090256109 | CONDITIONING AGENT FOR THE ETCHING OF ENAMEL LESIONS - The invention relates to a composition which comprises
| 10-15-2009 |
| 20090182425 | Sheet or Tubular Structure Consisting of Elastic Biocompatible Material and its Use - The present invention relates to a sheet or tubular structure consisting of biocompatible material, which is elastic and comprises at least one biologically active substance in at least one region and to a sheet or tubular structure, which comprises at least one biologically active substance release-modifying agent in at least one region as well as an implant covered at least partially by the sheet or tubular structure of the invention. The present invention further provides a method and an apparatus for producing, and preferably customizing and/or optimizing, the sheet or tubular structure of the invention. The sheet or tubular structure of the invention can be customized/optimized before implantation in the operating room. | 07-16-2009 |
| 20090130116 | Use of CEACAM8-Specific Substances for Treating Autoimmune Diseases and a Method for Screening Substances Which Induce Apoptosis - The invention relates to the use of substances which are specific to CEACAM8 for the manufacture of a medicament for the prophylactic or therapeutic treatment of human autoimmune diseases and/or gout. Another object of the invention concerns the use of CEACAM8-specific substances for apoptosis induction in-vitro. The invention also relates to a method for screening substances which induce apoptosis and a method for inducing apoptosis in human granulocytes. | 05-21-2009 |
| 20090005338 | Carbonyl-substituted titanocenes - A medicament containing a compound of the following formulas (Ia) and (Ib): | 01-01-2009 |
